Development of cancer therapeutic technology by functional measurement and control of cell division.
| Project/Area Number |
18590540
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Laboratory medicine
|
|---|
| Research Institution | Tokai University |
|---|
Principal Investigator |
TANAKA Tomoo Tokai University, School of Medicine, Assistant Professor (50192175)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TANAKA Manami National Institute of Advanced Industrial Science and Technology, Bradeion project, Project Leader (80188341)
KIJIMA Hiroshi Hirosaki Universiy, School of Medicne, Professor (90204859)
YAMAGUCHI Masamisu Kyoto Institute of Technology, Department of Applied Biology, Professor (00182460)
|
|---|
| Project Period (FY) |
2006 – 2007
|
| Project Status |
Completed (Fiscal Year 2007)
|
| Budget Amount *help |
¥3,950,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2007: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2006: ¥2,000,000 (Direct Cost: ¥2,000,000)
|
|---|
| Keywords | Bradeion / cancer marker / cancer diagnosis / development of cure monitor technique / structure analysis / measurement of enzyme activi / fluorescence correlation spectroscopy(FCS) / development of anticancer drua / 癌マーカ / Septin 4 / GTPase / 大腸菌 / 前立腺癌 / 癌 / 診断法 / 金コロイド / 表面プラズモン共鳴 / 高速原子間力顕微鏡 / 免疫電子顕微鏡法 |
|---|
| Research Abstract |
We have developed a technology for early diagnosis and cure monitor of cancer with Bradeion, a cancer marker we found. We have also developed the technology of Bradeion assay for discovering anticancer agent. As a result, we succeeded in the development of a cancer diagnosis system and kit. In addition, we succeeded in the structure analysis and the characterization of Bradeion, and development of the technology measuring inhibiting effect by the establishment of the method measuring its enzyme activity. In the last year of the study period, we used a fluorescence correlation spectroscopy (FCS) detecting single target molecule in patient serum. This full automatic machine with confocal laser microscope can measure using 10 pI of serum with a minute, and it costs only \1 per specimen. 3, 000 samples can be measured within one week. The data is reproducible in the samples stored at room temperature for a week. The samples preserved in a refrigerator are stable for a month.
The structure presentation of a material with originality did not succeed after all until now, though many projects for protein structure analysis flooded. On the other hand, we succeed in the structure analysis of the cancer marker, Bradeion, as a result that we narrowed down to only one useful material and centralized the methodology that complies with a purpose. It is not only medicinal benefits but also less toxicity that is important to select the candidate of and cancer drug. We therefore equipped animal models for the toxic examination using a Drosophila and a chimera mouse(patented). We investigate an inhibitor from structure analysis of Bradeion protein and perform a high throughput screening using the FCS. We aim at development of an anticancer agent, by performing the evaluation of the candidate selected by the screening and a toxic examination by the animal model.
|
Report
(3 results)
Research Products
(26 results)
-
-
-
-
-
-
-
[Presentation] ブラディオン・プロジェクト:創薬2007
Author(s)
田中 真奈実, 田中 朝雄, 山口 政光, 井上 喜博, Garratt, R.C.
Organizer
オミックス医療が拓く未来2007シンポジウム
Place of Presentation
学術総合センター
Description
「研究成果報告書概要(和文)」より
Related Report
-
-
-
-
-
-
-
[Presentation] Bradeion Project : Gene Targeting2007
Author(s)
Manami, Tanaka, Tomoo, Tanaka
Organizer
The first international Symposium on Omics-based Medicine and Systems Pathobiology, Japanese Association for Omics-based Medicine
Place of Presentation
National Center of Sciences
Description
「研究成果報告書概要(欧文)」より
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
